Actively Recruiting

Phase 2
Age: 55Years - 90Years
All Genders
ID06557460

A Phase IIb Randomized, Assessor-Masked, Multicenter Clinical Trial to Assess the Safety and Efficacy of Subretinal Implantation of the CPCB-RPE1 Implant in Advanced Dry Age-Related Macular Degeneration (Geographic Atrophy)

Led by Regenerative Patch Technologies, LLC · Updated on 2026-03-25

24

Participants Needed

5

Research Sites

678 weeks

Total Duration

On this page

Sponsors

R

Regenerative Patch Technologies, LLC

Lead Sponsor

C

California Institute for Regenerative Medicine (CIRM)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are conducting a Phase IIb randomized clinical trial to evaluate the safety and effects of the CPCB-RPE1 implant in people with geographic atrophy involving the fovea, a form of advanced dry age-related macular degeneration (AMD). This study aims to better understand how this subretinal implant may impact retinal sensitivity and visual acuity in affected individuals. Participants will be randomly assigned in a 3:1 ratio to receive either the surgical implantation of the CPCB-RPE1 device or a simulated sham implantation procedure. Up to 24 subjects across multiple centers will participate, with up to 18 receiving the active implant and up to 6 undergoing the sham surgery. The implant is placed under the retina through a surgical approach, and the control group receives a procedure mimicking surgery without implant placement. During the study, participants will undergo baseline and follow-up retinal sensitivity testing and visual acuity assessments, with primary outcomes measured one year after implantation. Researchers will monitor safety and efficacy throughout the study, including the ability of participants to complete microperimetry testing and post-operative care. The study will continue until December 2040, covering the screening, treatment, and outcome evaluation periods.

CONDITIONS

Brief Title

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Who Can Participate

Age: 55Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 55 to 90 years (inclusive)
  • Geographic atrophy involving the fovea in advanced dry age-related macular degeneration
  • Clinical evidence of geographic atrophy area between 4.0 mm2 and 15.0 mm2 involving the fovea
  • Geographic atrophy confirmed by biomicroscopy, OCT, or FAF
  • Best-corrected visual acuity in the eye to receive implant between 20/200 and 20/63 inclusive
  • Eye not receiving the implant must have visual acuity equal or better than the implanted eye
  • Medically suitable for pars plana vitrectomy and surgical implant procedure
  • Medically suitable for general anesthesia or monitored intravenous sedation if needed
  • Pseudophakic in the study eye (intraocular lens implant present)
  • Willing and able to provide written informed consent
  • Able to complete baseline microperimetry retinal sensitivity testing
  • Baseline microperimetry shows at least 5 spots in the perilesional region with retinal sensitivity between 3 and 17 Db
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Up to 1 week

Participants undergo surgical implantation of the CPCB-RPE1 implant or a simulated sham implantation procedure, followed by immediate post-operative care.

1 surgery visit and several immediate post-operative visits

Post-operative Follow-up

Duration - Approximately 1 year

Participants attend follow-up visits to monitor safety and assess the efficacy of the implant, including changes in retinal sensitivity and visual acuity.

Regular follow-up visits during the year post implantation

Trial Site Locations

Total: 5 locations

1

Retina-Vitreous Associates Medical Group

Beverly Hills, California, United States, 90211

Actively Recruiting

2

Retina Associates of Southern California

Huntington Beach, California, United States, 92647

Actively Recruiting

3

USC - Keck

Los Angeles, California, United States, 90033

Actively Recruiting

4

University Retina

Lemont, Illinois, United States, 60439

Actively Recruiting

5

Retina Consultants of Texas

The Woodlands, Texas, United States, 77384

Actively Recruiting

Loading map...

Research Team

C

Clinical Research

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Long-term Extension Study of JNJ-81201887 in Participants Wi...

Geographic Atrophy

Actively Recruiting

104 locations

A Prospective Observational Study to Assess the Reliability ...

Macular Degeneration

Actively Recruiting

1 location

A Multi-Center Registry Study to Assess the Safety and Effec...

Dry Age-related Macular Degeneration

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here